{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:00:36Z","timestamp":1759939236290,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00280-023-04611-x","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T18:01:58Z","timestamp":1699898518000},"page":"627-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?"],"prefix":"10.1007","volume":"93","author":[{"given":"Mourad","family":"Hamimed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Jean","family":"Weiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Schiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawel","family":"Belmecheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Etienne-Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1733-3410","authenticated-orcid":false,"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Harbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"4611_CR1","doi-asserted-by":"publisher","first-page":"pkaa115","DOI":"10.1093\/jncics\/pkaa115","volume":"5","author":"MAJ Lafolla","year":"2020","unstructured":"Lafolla MAJ, Yang C, Chandran V et al (2020) Predicting toxicity and response to pembrolizumab through germline genomic HLA class 1 analysis. JNCI Cancer Spectr 5:pkaa115","journal-title":"JNCI Cancer Spectr"},{"key":"4611_CR2","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","volume":"19","author":"Y Feng","year":"2013","unstructured":"Feng Y, Roy A, Masson E et al (2013) Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19:3977\u20133986","journal-title":"Clin Cancer Res"},{"key":"4611_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/psp4.12132","volume":"6","author":"J Elassaiss-Schaap","year":"2017","unstructured":"Elassaiss-Schaap J, Rossenu S, Lindauer A et al (2017) Using model-based \u201cLearn and Confirm\u201d to reveal the pharmacokinetics-pharmacodynamics relationship of Pembrolizumab in the KEYNOTE-001 Trial. CPT Pharmacometr Syst Pharmacol 6:21\u201328","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"4611_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/ph14080796","volume":"14","author":"C Marin","year":"2021","unstructured":"Marin C, Khoudour N, Millet A et al (2021) Cross-validation of a multiplex LC-MS\/MS method for assaying mAbs plasma levels in patients with cancer: a GPCO-UNICANCER study. Pharmaceuticals (Basel) 14:796","journal-title":"Pharmaceuticals (Basel)"},{"key":"4611_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/psp4.12139","volume":"6","author":"M Ahamadi","year":"2017","unstructured":"Ahamadi M, Freshwater T, Prohn M et al (2017) Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometr Syst Pharmacol 6:49\u201357","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"4611_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.4161\/mabs.24815","volume":"5","author":"C Passot","year":"2013","unstructured":"Passot C, Azzopardi N, Renault S et al (2013) Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies. MAbs 5:614\u2013619","journal-title":"MAbs"},{"key":"4611_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","volume":"10","author":"X Chen","year":"2019","unstructured":"Chen X, Song X, Li K, Zhang T (2019) FcgammaR-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy. Front Immunol 10:292","journal-title":"Front Immunol"},{"key":"4611_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","volume":"44","author":"H Li","year":"2017","unstructured":"Li H, Yu J, Liu C, et al (2017) Time dependent pharmacokinetics of Pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn 44:403\u2013414","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4611_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/jmedgenet-2018-105485","volume":"56","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Snyder GD, Nikiforow S et al (2019) Haemophagocytic lymphohistiocytosis complicating Pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism. J Med Genet 56:39\u201342","journal-title":"J Med Genet"},{"key":"4611_CR10","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","volume":"24","author":"DC Turner","year":"2018","unstructured":"Turner DC, Kondic AG, Anderson KM et al (2018) Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res 24:5841\u20135849","journal-title":"Clin Cancer Res"},{"key":"4611_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/jcph.1984","volume":"62","author":"CJ Peer","year":"2022","unstructured":"Peer CJ, Heiss BL, Goldstein DA et al (2022) Pharmacokinetic simulation analysis of less frequent nivolumab and pembrolizumab dosing: pharmacoeconomic rationale for dose deescalation. J Clin Pharmacol 62:532\u2013540","journal-title":"J Clin Pharmacol"},{"key":"4611_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960116","volume":"12","author":"F de Vries","year":"2023","unstructured":"de Vries F, Smit AAJ, Wolbink G et al (2023) Case report: pharmacokinetics of Pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration. Front Oncol 12:960116","journal-title":"Front Oncol"},{"key":"4611_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.lungcan.2023.02.009","volume":"178","author":"N Wang","year":"2023","unstructured":"Wang N, Zheng L, Li M et al (2023) Clinical efficacy and safety of individualized Pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: a prospective exploratory clinical trial. Lung Cancer 178:183\u2013190","journal-title":"Lung Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04611-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T17:01:57Z","timestamp":1716829317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["4611"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04611-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"15 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest with the reported data or case presentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Treatment, sampling for biological analyze including drug monitoring, and clinical evaluations were all performed following standard practice in our institute in all patients with cancer and not part of an experimental protocol. Genotyping was not part of routine care and written informed consent was thus obtained from the patient prior to perform germinal genotyping of the <i>FCGR2A<\/i> and <i>FCGR3A<\/i> genes, following the French Biomedicine Agency guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Authorization was waived because in this case report, no potentially identifiable images or data related to the patient are displayed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patients authorization to publish the case"}}]}}